Proteome Sciences plc  

(Public, LON:PRM)   Watch this stock  
Find more results for John Haigh�
-0.35 (-1.87%)
Jul 28 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 18.28 - 19.75
52 week 13.00 - 23.94
Open 19.00
Vol / Avg. 295,088.00/221,365.00
Mkt cap 41.27M*
P/E     -
Div/yield     -
EPS -0.01*
Shares 227.97M
Beta     -
Inst. own     -
May 18, 2016
Full Year 2015 Proteome Sciences PLC Earnings Release

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -123.70% -144.42%
Operating margin -144.04% -163.71%
EBITD margin - -142.72%
Return on average assets -28.31% -31.94%
Return on average equity - -
Employees 35 -
CDP Score - -


Coveham House, Downside Bridge Road
United Kingdom - Map
+44-1932-865065 (Phone)
+44-1932-868696 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Proteome Sciences plc is a protein biomarker company. The Company's principal activity includes biomarker research and development in applied proteomics and workflows using techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. It operates through three geographic regions: the United Kingdom, Germany and the United States. Through the United Kingdom segment, it provides protein separation and mass spectrometry capabilities for identification and analysis of post-translational modification of proteins particularly in protein phosphorylation, image analysis and bioinformatics. Through the Germany segment, it provides protein profiling technologies, including Tandem Mass Tags (TMT), which offers quantitation of various proteins for the discovery of biomarkers mass spectrometry. PS Biomarker Services provides integrated proteomic services for biomarker discovery, validation and assay development.

Officers and directors

Christopher D. J. Pearce Executive Chairman of the Board
Age: 52
Jeremy Haigh Chief Executive Officer, Director
Geoffrey John Ellis Finance Director, Company Secretary, Director
Age: 53
Ian H. Pike Chief Operating Officer, Executive Director
Malcolm Ward Chief Technical Officer - London Research Facility
Glenn Barney Vice President - Business Development, USA
Josef Schwarz Head - Projects & Production, Proteome Sciences R&D
Gee See Chee Director of Personalised Medicine
William Dawson Non-Executive Director
Martin Diggle Non-Executive Director
Age: 52